Federal Capture Intelligence

Top HHS research and development in biotechnology (except nanobiotechnology) contractors (NAICS 541714)

Contract actions: October 1, 2021 – October 23, 2026 Updated October 24, 2026 Department of Health and Human Services agency guide NAICS 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
Latest 12 months
$1.7B
Net obligations · Up $701.8M vs. $986.4M preceding
Prime contractors
205
With positive obligations in the latest 12 months

Research the HHS federal contracting market for research and development in biotechnology (except nanobiotechnology) under NAICS 541714. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.

Contract obligation trends for Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services

Federal records show $12.4B in net obligations across 1,788 awards in Research and Development in Biotechnology (except Nanobiotechnology) at the Department of Health and Human Services from Oct 1, 2021 through Oct 23, 2026. This market accounts for 8.3% of $150.2B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations increased 71.1% from $986.4M to $1.7B. 21 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY27 is year-to-date through Oct 23, 2026; earlier years show complete fiscal-year totals.

FY27 year-to-date: $2.0M versus −$15.0M through the same date in FY26 (Not comparable).
Net obligations · complete fiscal yearNet obligations · FY27 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B1,024Complete
FY2023$4.5B1,109Complete
FY2024$3.2B1,261Complete
FY2025$1.0B1,163Complete
FY2026$1.7B922Complete

Market at a glance

All reported prime contract awards
All-period net obligations
$12.4B
1,788 awards · 705 prime contractors
Latest 12-month movement
+71.1%
$1.7B vs. $986.4M
Leading eight prime share
59.0%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
8.3% of $150.2B in agency-wide net obligations.
Set-aside share when reported
10.9% of 1,215 awards with reported set-aside status.
Set-aside reporting
132 set aside · 1,083 no set-aside · 573 not reported

What changed in the last 12 months?

Oct 24, 2025–Oct 23, 2026, compared with Oct 24, 2024–Oct 23, 2025.

Market structure

Top-five contractor share increased
31.1%→45.9%+14.8 percentage points
Contractors outside the top five now account for 54.1% of positive obligations.

Competitive shifts

PPD DEVELOPMENT LP climbed the most in the contractor rankings
#117→#10Up 107 places
The contractor accounts for 2.3% of positive obligations across 11 reported actions.
SHIONOGI INC was the largest newly observed contractor
$156.1MLatest 12-month obligations
First observed in this market on Apr 6, 2026, the contractor now ranks #2 by positive obligations across 2 reported actions.

Buyer demand

Reported obligations through BARDA - ASPR / DAAPPO / BARDA DCMA increased
$912.2M→$1.2B+$337.8M
Latest-period activity spans 149 awards across 87 prime contractors.

Award activity

View 4 additional material changes

Competitive shifts

SIGA TECHNOLOGIES, INC. lost the most market share
4.26%→0.12%−4.1 percentage points
The contractor now ranks #72 by positive obligations, based on 2 reported actions.
UNIVERSITY LAB PARTNERS recorded the largest net deobligation
$19.1M→−$17.5M−$36.6M
The contractor now is unranked by positive obligations, based on 1 reported action.

Buyer demand

Reported obligations through NATIONAL INSTITUTES OF HEALTH decreased
$27.0M→$8.6M−$18.4M
Latest-period activity spans 2 awards across 2 prime contractors.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Federal contract obligations by funding office

See how positive obligations were attributed across funding offices in the 12 months ending Oct 23, 2026.

73.9% of positive obligations were attributed to BARDA - ASPR / DAAPPO / BARDA DCMA. That represents $1.2B, up $337.8M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. BARDA - ASPR / DAAPPO / BARDA DCMA73.9% · $1.2B · up $337.8M
  2. NATIONAL INSTITUTES OF HEALTH NIAID9.9% · $167.3M · up $40.9M
  3. OFC ASST SEC FOR PREPARENESS RES8.4% · $142.1M · up $102.5M
  4. FDA OFFICE OF ACQ GRANT SVCS2.3% · $38.1M · up $12.1M
  5. NATIONAL INSTITUTES OF HEALTH NIDA1.9% · $32.9M · up $13.6M
  6. All other reported offices3.6% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #1Rank unchanged

    Latest 12 months

    $1.2B

    73.9% of positive obligations

    Versus preceding 12 months

    +$337.8M

    87 active prime contractors · 149 awards

    View office comparison and evidence

    Reported obligations increased 37.0% from $912.2M to $1.2B. The office’s share of positive obligations moved from 76.9% to 73.9%, a change of −3.0 percentage points.

    The latest period contains 240 actions across 149 awards and 15 newly active prime contractors. The preceding period contained 118 active prime contractors and 172 awards.

    Leading award-level changes

  2. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIAID

    #2Rank unchanged

    Latest 12 months

    $167.3M

    9.9% of positive obligations

    Versus preceding 12 months

    +$40.9M

    88 active prime contractors · 167 awards

    View office comparison and evidence

    Reported obligations increased 32.3% from $126.4M to $167.3M. The office’s share of positive obligations moved from 10.7% to 9.9%, a change of −0.8 percentage points.

    The latest period contains 246 actions across 167 awards and 19 newly active prime contractors. The preceding period contained 89 active prime contractors and 163 awards.

  3. Reported funding office

    OFC ASST SEC FOR PREPARENESS RES

    #3Rank unchanged

    Latest 12 months

    $142.1M

    8.4% of positive obligations

    Versus preceding 12 months

    +$102.5M

    16 active prime contractors · 21 awards

    View office comparison and evidence

    Reported obligations increased 258.8% from $39.6M to $142.1M. The office’s share of positive obligations moved from 3.3% to 8.4%, a change of +5.1 percentage points.

    The latest period contains 32 actions across 21 awards and 9 newly active prime contractors. The preceding period contained 19 active prime contractors and 20 awards.

  4. Reported funding office

    FDA OFFICE OF ACQ GRANT SVCS

    #4Up 1 from #5

    Latest 12 months

    $38.1M

    2.3% of positive obligations

    Versus preceding 12 months

    +$12.1M

    62 active prime contractors · 89 awards

    View office comparison and evidence

    Reported obligations increased 46.5% from $26.0M to $38.1M. The office’s share of positive obligations moved from 2.2% to 2.3%, a change of +0.1 percentage points.

    The latest period contains 104 actions across 89 awards and 22 newly active prime contractors. The preceding period contained 69 active prime contractors and 92 awards.

  5. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIDA

    #5Up 1 from #6

    Latest 12 months

    $32.9M

    1.9% of positive obligations

    Versus preceding 12 months

    +$13.6M

    22 active prime contractors · 30 awards

    View office comparison and evidence

    Reported obligations increased 70.5% from $19.3M to $32.9M. The office’s share of positive obligations moved from 1.6% to 1.9%, a change of +0.3 percentage points.

    The latest period contains 52 actions across 30 awards and 9 newly active prime contractors. The preceding period contained 24 active prime contractors and 28 awards.

  6. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #6Up 1 from #7

    Latest 12 months

    $15.6M

    0.92% of positive obligations

    Versus preceding 12 months

    −$841K

    5 active prime contractors · 5 awards

    View office comparison and evidence

    Reported obligations decreased 5.1% from $16.4M to $15.6M. The office’s share of positive obligations moved from 1.4% to 0.92%, a change of −0.5 percentage points.

    The latest period contains 5 actions across 5 awards and 3 newly active prime contractors. The preceding period contained 6 active prime contractors and 17 awards.

  7. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NICHD

    #7Up 3 from #10

    Latest 12 months

    $9.5M

    0.56% of positive obligations

    Versus preceding 12 months

    +$6.1M

    23 active prime contractors · 52 awards

    View office comparison and evidence

    Reported obligations increased 174.5% from $3.5M to $9.5M. The office’s share of positive obligations moved from 0.29% to 0.56%, a change of +0.3 percentage points.

    The latest period contains 73 actions across 52 awards and 3 newly active prime contractors. The preceding period contained 24 active prime contractors and 61 awards.

  8. Reported funding office

    ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

    #8New to the positive-obligation ranking

    Latest 12 months

    $8.6M

    0.51% of positive obligations

    Versus preceding 12 months

    +$8.6M

    7 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations rose from $0 to $8.6M. The office’s share of positive obligations moved from 0% to 0.51%, a change of +0.5 percentage points.

    The latest period contains 23 actions across 7 awards and 7 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.

  9. Reported funding office

    NATIONAL INSTITUTES OF HEALTH (75N95B)

    #9Down 5 from #4

    Latest 12 months

    $8.6M

    0.51% of positive obligations

    Versus preceding 12 months

    −$18.4M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations decreased 68.2% from $27.0M to $8.6M. The office’s share of positive obligations moved from 2.3% to 0.51%, a change of −1.8 percentage points.

    The latest period contains 3 actions across 2 awards and 1 newly active prime contractor. The preceding period contained 5 active prime contractors and 7 awards.

    Leading award-level changes

  10. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #10Down 2 from #8

    Latest 12 months

    $7.6M

    0.45% of positive obligations

    Versus preceding 12 months

    +$1.8M

    21 active prime contractors · 23 awards

    View office comparison and evidence

    Reported obligations increased 30.1% from $5.8M to $7.6M. The office’s share of positive obligations moved from 0.49% to 0.45%, a change of 0.0 percentage points.

    The latest period contains 36 actions across 23 awards and 11 newly active prime contractors. The preceding period contained 15 active prime contractors and 17 awards.

  11. Reported funding office

    NATIONAL INSTITUTES OF HEALTH (75N94A)

    #12Rank unchanged

    Latest 12 months

    $1.9M

    0.11% of positive obligations

    Versus preceding 12 months

    −$350K

    3 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations decreased 15.7% from $2.2M to $1.9M. The office’s share of positive obligations moved from 0.19% to 0.11%, a change of −0.1 percentage points.

    The latest period contains 7 actions across 4 awards and 2 newly active prime contractors. The preceding period contained 4 active prime contractors and 5 awards.

  12. Reported funding office

    NIH NCI

    #13Down 4 from #9

    Latest 12 months

    $1.6M

    0.090% of positive obligations

    Versus preceding 12 months

    −$2.2M

    13 active prime contractors · 31 awards

    View office comparison and evidence

    Reported obligations decreased 57.9% from $3.8M to $1.6M. The office’s share of positive obligations moved from 0.32% to 0.090%, a change of −0.2 percentage points.

    The latest period contains 38 actions across 31 awards and 5 newly active prime contractors. The preceding period contained 15 active prime contractors and 34 awards.

  13. Reported funding office

    ASPR BARDA DIV CONTRACTS MGMT & ACQ

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    +$200.0M

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations moved from $200.0M in net deobligations to $0 in net obligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 1 active prime contractor and 1 award.

  14. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NIA

    No positive-obligation rank

    Latest 12 months

    −$3.3M

    0% of positive obligations

    Versus preceding 12 months

    −$3.2M

    7 active prime contractors · 7 awards

    View office comparison and evidence

    Reported obligations widened from $103K to $3.3M in net deobligations. The office’s share of positive obligations moved from 0% to 0%, a change of 0.0 percentage points.

    The latest period contains 8 actions across 7 awards and 6 newly active prime contractors. The preceding period contained 3 active prime contractors and 3 awards.

Contract types, competition, and procurement methods

From Oct 24, 2025 through Oct 23, 2026, 325 awards had positive obligations totaling $1.7B. Np was the leading reported procedure, accounting for 69.4% of positive obligations. Awards with a reported parent IDV accounted for 19.9%. Reported awards used contract vehicles such as CARRRP and BARDA Nonclinical Development Biological.

Leading award type
79.7%
Definitive Contract
Leading reported procedure
69.4%
Np
Reported parent IDV
19.9%
of positive obligations had a reported parent IDV
Median reported offers
1
225 of 325 awards reported offers

Observed contract vehicles

Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.

Buying method changes

Compared with Oct 24, 2024–Oct 23, 2025. Based on 325 current awards and 357 preceding awards with positive net obligations.

Reported full-and-open obligation share
25.0%
Down from 92.4% in the preceding period
Median positive award obligations
$638K
Up from $355K in the preceding period
Parent-IDV obligation share
19.9%
Down from 31.3% in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

Same-NAICS comparison

Compared with the NAICS 541714 peer median, parent-IDV obligation share is 31.2 percentage points lower, reported full-and-open obligation share is 13.7 percentage points higher, delivery-order obligation share is 31.2 percentage points lower, and median positive award obligations are 1249.2% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share19.9%51.1%-31.2 pts
Reported full-and-open obligation share25.0%11.3%+13.7 pts
Delivery-order obligation share19.9%51.1%-31.2 pts
Median positive award obligations$638K$47K+1249.2%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)127$1.4B79.7%
Delivery Order(C)143$347.9M19.9%
Purchase Order(B)54$6.8M0.39%
BPA Call(A)1$20K0%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
IDC(B)142$347.6M19.9%
FSS(C)1$215K0.010%
BPA(E)1$20K0%
Not reported181$1.4B80.1%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Single Award(S)101$325.0M18.6%
Multiple Award(M)43$22.9M1.3%
Not reported181$1.4B80.1%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Np(NEGOTIATED PROPOSAL/QUOTE)103$1.2B69.4%
Negotiated Proposal/Quote(NP)96$447.7M25.6%
Br(BASIC RESEARCH)18$28.4M1.6%
Sss(ONLY ONE SOURCE)4$23.2M1.3%
Subject to Multiple Award Fair Opportunity(MAFO)31$16.9M0.97%
Sp1(SIMPLIFIED ACQUISITION)32$6.9M0.40%
Other reported values41$12.1M0.69%

Extent competed

Reported valueAwardsPositive obligationsShare
A(FULL AND OPEN COMPETITION)124$1.2B70.4%
Full and Open Competition(A)118$436.5M25.0%
Full and Open Competition After Exclusion of Sources(D)11$30.1M1.7%
C(NOT COMPETED)4$23.2M1.3%
D(FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES)9$16.5M0.94%
F(COMPETED UNDER SAP)20$5.5M0.32%
Other reported values39$5.5M0.32%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Fair Opportunity Given(FAIR)39$21.1M1.2%
Only One Source - Other(ONE)3$1.3M0.080%
Follow-on Action Following Competitive Initial Action(FOO)1$498K0.030%
Not reported282$1.7B98.7%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)8$23.6M1.4%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$2.4M0.13%
SAP Non-Competition (FAR 13)(SP2)24$2.2M0.13%
Less Than or Equal to the Micro-Purchase Threshold(MPT)1$14K0%
Not reported291$1.7B98.4%

Contract pricing types

Reported valueAwardsPositive obligationsShare
U(COST PLUS FIXED FEE)46$779.7M44.6%
J(FIRM FIXED PRICE)83$322.0M18.4%
Firm Fixed Price(J)56$178.3M10.2%
Cost Plus Fixed Fee(U)46$131.0M7.5%
T(COST SHARING)6$99.6M5.7%
Cost Sharing(T)4$89.7M5.1%
Other reported values84$148.5M8.5%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Health R&d Services; Health Care Services; Experimental Development(AN13)46$526.3M30.1%
Drugs and Biologicals(6505)13$351.9M20.1%
Health R&d Services; Health Care - Other; Applied Research(AN42)17$342.8M19.6%
Health R&d Services; Health Care Services; Basic Research(AN11)66$215.3M12.3%
Health R&d Services; Health Care Services; Applied Research(AN12)91$144.2M8.2%
Surgical Dressing Materials(6510)1$34.9M2.0%
Other reported values91$133.4M7.6%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)73$1.4B81.8%
National Institutes of Health(7529)185$256.1M14.7%
Food and Drug Administration(7524)41$45.7M2.6%
Departmental Offices(1406)7$8.6M0.49%
Centers for Disease Control and Prevention(7523)18$7.6M0.44%
Indian Health Service(7527)1$215K0.010%

Awarding offices

Reported valueAwardsPositive obligationsShare
Barda - Aspr / Daappo / Barda Dcma(75A501)73$1.4B81.8%
National Institutes of Health Niaid(75N930)80$161.0M9.2%
National Institutes of Health Nida(75N950)15$55.6M3.2%
Fda Office of Acq Grant Svcs(75F401)41$45.7M2.6%
National Institutes of Health Olao(75N980)41$24.3M1.4%
National Institutes of Health Nichd(75N940)42$11.3M0.64%
Other reported values33$20.4M1.2%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
75A50123D00005(7505)1$145.1M8.3%
75N93021D00035(7529)3$37.2M2.1%
75N93021D00038(7529)3$21.9M1.3%
75N95024D00038(7529)1$14.8M0.85%
75A50122D00017(7505)6$12.7M0.73%
75A50122D00003(7505)4$11.3M0.65%
75N93024D00044(7529)1$8.1M0.46%
75N95023D00006(7529)1$7.4M0.42%
Other reported values124$89.4M5.1%
Not reported181$1.4B80.1%

Exact vehicle-match evidence

Reported award data linked 19 awards to a specific catalog vehicle.

Offers, award size, and timing

Median reported offers
1 median
225 reported · 100 not reported
Positive award obligations
$638K median
$126K–$2.0M middle 50%
Reported performance period
882 days (~2.4 years) median
325 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Oct 23, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Top federal contractors

Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.

Prime contractor concentration
21 of 205prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
15.4%of positive obligations in the last 12 months
Leading four prime contractors
40.1%of positive obligations in the last 12 months
Leading eight prime contractors
59.0%of positive obligations in the last 12 months

Based on $1.7B in positive obligations during the 12 months ending Oct 23, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Oct 24, 2024–Oct 23, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $266.2M

    15.4%

    Dollar movement

    +$195.8M

    vs. prior 12 months

    Last 12mo awards

    3 awards

    5 actions

    Historical and award details for ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
    Obligations: prior → latest
    $70.4M → $266.2M
    +278.2%
    Share: prior → latest
    5.6% → 15.4%
    +9.8 percentage points
    All-period obligations
    $497.0M
    4.0% of all-period positive obligations · 3 awards
    Recorded activity
    Since Nov 4, 2021
    through Sep 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside32
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $156.1M

    9.0%

    Dollar movement

    +$156.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for SHIONOGI INC
    Obligations: prior → latest
    $0 → $156.1M
    Not comparable
    Share: prior → latest
    0% → 9.0%
    +9.0 percentage points
    All-period obligations
    $156.1M
    1.3% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 6, 2026
    through Aug 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $145.1M

    8.4%

    Dollar movement

    +$345.7M

    vs. prior 12 months

    Last 12mo awards

    7 awards

    9 actions

    Historical and award details for ADVANCED TECHNOLOGY INTERNATIONAL
    Obligations: prior → latest
    −$200.6M → $145.1M
    Not comparable
    Share: prior → latest
    0% → 8.4%
    +8.4 percentage points
    All-period obligations
    $3.5B
    28.0% of all-period positive obligations · 8 awards
    Recorded activity
    Since Sep 27, 2023
    through Sep 29, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported75
    Reported small business00
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $126.0M

    7.3%

    Dollar movement

    +$36.1M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for AMGEN USA INC
    Obligations: prior → latest
    $89.9M → $126.0M
    +40.1%
    Share: prior → latest
    7.2% → 7.3%
    +0.1 percentage points
    All-period obligations
    $840.7M
    6.8% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 28, 2022
    through Aug 4, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside12
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $99.8M

    5.8%

    Dollar movement

    +$73.8M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for KALEO, INC.
    Obligations: prior → latest
    $26.0M → $99.8M
    +284.1%
    Share: prior → latest
    2.1% → 5.8%
    +3.7 percentage points
    All-period obligations
    $129.3M
    1.0% of all-period positive obligations · 2 awards
    Recorded activity
    Since Apr 11, 2024
    through Sep 28, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside21
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $89.1M

    5.2%

    Dollar movement

    −$16.2M

    vs. prior 12 months

    Last 12mo awards

    1 award

    5 actions

    Historical and award details for START2 GROUP, INC.
    Obligations: prior → latest
    $105.2M → $89.1M
    −15.4%
    Share: prior → latest
    8.4% → 5.2%
    −3.3 percentage points
    All-period obligations
    $227.1M
    1.8% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 9, 2024
    through Sep 26, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $83.1M

    4.8%

    Dollar movement

    +$33.1M

    vs. prior 12 months

    Last 12mo awards

    4 awards

    14 actions

    Historical and award details for MAPP BIOPHARMACEUTICAL, INC.
    Obligations: prior → latest
    $50.0M → $83.1M
    +66.2%
    Share: prior → latest
    4.0% → 4.8%
    +0.8 percentage points
    All-period obligations
    $393.2M
    3.2% of all-period positive obligations · 4 awards
    Recorded activity
    Since Nov 2, 2021
    through Sep 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside44
    Not reported00
    Reported small business22
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $54.9M

    3.2%

    Dollar movement

    −$8.9M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
    Obligations: prior → latest
    $63.8M → $54.9M
    −14.0%
    Share: prior → latest
    5.1% → 3.2%
    −1.9 percentage points
    All-period obligations
    $147.4M
    1.2% of all-period positive obligations · 2 awards
    Recorded activity
    Since Sep 18, 2024
    through Oct 7, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $48.9M

    2.8%

    Dollar movement

    +$48.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    3 actions

    Historical and award details for OSSIUM HEALTH, INC.
    Obligations: prior → latest
    $0 → $48.9M
    Not comparable
    Share: prior → latest
    0% → 2.8%
    +2.8 percentage points
    All-period obligations
    $69.9M
    0.56% of all-period positive obligations · 1 award
    Recorded activity
    Since Aug 8, 2024
    through Sep 4, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  10. #10

    Last 12mo obligations

    $40.1M

    2.3%

    Dollar movement

    +$39.4M

    vs. prior 12 months

    Last 12mo awards

    7 awards

    11 actions

    Historical and award details for PPD DEVELOPMENT LP
    Obligations: prior → latest
    $621K → $40.1M
    +6350.1%
    Share: prior → latest
    0.050% → 2.3%
    +2.3 percentage points
    All-period obligations
    $339.2M
    2.7% of all-period positive obligations · 11 awards
    Recorded activity
    Since Oct 28, 2021
    through Oct 14, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside32
    Not reported44
    Reported small business00
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $34.9M

    2.0%

    Dollar movement

    +$34.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for VERICEL CORPORATION
    Obligations: prior → latest
    $0 → $34.9M
    Not comparable
    Share: prior → latest
    0% → 2.0%
    +2.0 percentage points
    All-period obligations
    $34.9M
    0.28% of all-period positive obligations · 1 award
    Recorded activity
    Since Apr 1, 2026
    through Apr 1, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $33.5M

    1.9%

    Dollar movement

    +$14.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PUBLIC HEALTH VACCINES LLC
    Obligations: prior → latest
    $19.5M → $33.5M
    +72.1%
    Share: prior → latest
    1.6% → 1.9%
    +0.4 percentage points
    All-period obligations
    $66.7M
    0.54% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 2, 2021
    through Jun 8, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    $33.2M

    1.9%

    Dollar movement

    +$33.2M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for CERUS CORPORATION
    Obligations: prior → latest
    $0 → $33.2M
    Not comparable
    Share: prior → latest
    0% → 1.9%
    +1.9 percentage points
    All-period obligations
    $65.4M
    0.52% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 20, 2024
    through Jul 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $31.7M

    1.8%

    Dollar movement

    +$31.7M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for SPECTRAL MD, INC.
    Obligations: prior → latest
    $0 → $31.7M
    Not comparable
    Share: prior → latest
    0% → 1.8%
    +1.8 percentage points
    All-period obligations
    $86.6M
    0.70% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 27, 2023
    through Aug 17, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $25.5M

    1.5%

    Dollar movement

    +$8.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for 4J THERAPEUTICS INC
    Obligations: prior → latest
    $17.0M → $25.5M
    +50.0%
    Share: prior → latest
    1.4% → 1.5%
    +0.1 percentage points
    All-period obligations
    $63.1M
    0.51% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 18, 2024
    through Sep 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

Potential federal contract recompetes

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

RHO FEDERAL SYSTEMS DIVISION INC

EO14398; AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)

The reported potential end date is Jan 31, 2027. Current award value is 100.0% of reported potential value ($40.1M of $40.1M).

Performance period

94.5%

As of Oct 23, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$40.1M current$40.1M potential
Supporting data

Reported performance starts Feb 1, 2022.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$40.1M is obligated against $40.1M in current reported award value (100.0%).

Reported potential end dates: Jan 31, 2023 → Jan 31, 2024 → Jan 31, 2025 → Jan 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93022C00003

DELOITTE CONSULTING LLP

SYSTEMIC HARMONIZATION AND INTEROPERABILITY ENHANCEMENT FOR LABORATORY DATA (SHI

The reported potential end date moved later 3 times in the latest 12 months.

Performance period

86.7%

As of Oct 23, 2026Potential end Jun 9, 2027

Current award value as a share of potential value

100.0%

$47.2M current$47.2M potential
Supporting data

Reported performance starts Sep 26, 2022.

No later potential end date is reported; current and potential end dates are both Jun 9, 2027.

$47.2M is obligated against $47.2M in current reported award value (100.0%).

Reported potential end dates: Sep 27, 2024 → Sep 27, 2025 → Mar 27, 2026 → Apr 26, 2026 → Jun 10, 2026 → Jun 9, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75F40122C00143

CRESTONE, INC.

TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS.

The reported potential end date is Jan 31, 2027. Current award value is 100.0% of reported potential value ($33.1M of $33.1M).

Performance period

96.3%

As of Oct 23, 2026Potential end Jan 31, 2027

Current award value as a share of potential value

100.0%

$33.1M current$33.1M potential
Supporting data

Reported performance starts Sep 9, 2019.

No later potential end date is reported; current and potential end dates are both Jan 31, 2027.

$33.1M is obligated against $33.1M in current reported award value (100.0%).

Reported potential end dates: Aug 11, 2023 → Oct 11, 2024 → Jan 31, 2026 → May 31, 2026 → Jan 31, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N93019C00056

VAXXAS PTY LTD

DEVELOPMENT OF HD-MICRO ARRAY PATCH (MAP) TO DELIVER A VACCINE AGAINST A PANDEMIC STRAIN OF INFLUENZA, H5N1.

The reported potential end date is Dec 30, 2026. Current award value is 100.0% of reported potential value ($29.6M of $29.6M).

Performance period

97.0%

As of Oct 23, 2026Potential end Dec 30, 2026

Current award value as a share of potential value

100.0%

$29.6M current$29.6M potential
Supporting data

Reported performance starts Sep 29, 2020.

No later potential end date is reported; current and potential end dates are both Dec 30, 2026.

$29.6M is obligated against $29.6M in current reported award value (100.0%).

Reported potential end dates: Jun 30, 2025 → Dec 30, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50120C00180

LOCUS BIOSCIENCES INC

THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1. ADD $14,773,583.00 OF SUPPLEMENTAL FUNDING TO CLIN 0002. 2. ADD $3,226,417.00 OF SUPPLEMENTAL FUNDING TO CLIN 0003.

$73.9M is obligated on an award with a reported potential end date of January 1, 2027.

Performance period

96.9%

As of Oct 23, 2026Potential end Jan 1, 2027

Current award value as a share of potential value

67.3%

$73.9M current$109.8M potential
Supporting data

Reported performance starts Sep 28, 2020.

Current performance is reported through Dec 31, 2026.

$73.9M is obligated against $73.9M in current reported award value (100.0%).

Reported potential end dates: Jan 30, 2026 → Mar 30, 2026 → Dec 31, 2026 → Jan 1, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50120C00169

ADVANCED TECHNOLOGY INTERNATIONAL

MODIFICATION UNDER RRPV OTA WITH ATI TO ADDRESS FUNDING GAPS IN INITIAL TASK ORDER.

$100.0M is obligated on an award with a reported potential end date of June 16, 2027.

Performance period

80.1%

As of Oct 23, 2026Potential end Jun 16, 2027

Current award value as a share of potential value

100.0%

$100.0M current$100.0M potential
Supporting data

Reported performance starts Mar 15, 2024.

No later potential end date is reported; current and potential end dates are both Jun 16, 2027.

$100.0M is obligated against $100.0M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50124F61006

These are research leads, not confirmed recompetes. USAspending records through Oct 23, 2026; reported dates and values can change through later modifications.

Recent federal contract award activity

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Base award

This action

+$223.8M

ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

BARDA - ASPR / DAAPPO / BARDA DCMA

STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP)

Why it stands out

The contractor climbed 2 positions in this market.

It now ranks #1 by positive obligations over the latest 12 months.

Award net obligations
$263.6M
Share of 12-month positive obligations
12.9%
Supporting data
Prime contractor
#1 · 15.4% share
up 2 ranks · +9.8 percentage points · $195.8M net increase; action exceeded it by $28.0M
Funding office
#1 · 73.9% attributed share
−3.0 percentage points · $337.8M net increase; action accounted for 66.3%
Related:Largest share gainFunding office gain
PIID 75A50126C00001
Base award

This action

+$119.2M

SHIONOGI INC

BARDA - ASPR / DAAPPO / BARDA DCMA

LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.

Why it stands out

No activity for this contractor was reported in this market during the preceding 12 months.

The base action placed the contractor #2 in this market by positive obligations over the latest 12 months.

Award net obligations
$156.1M
Share of 12-month positive obligations
6.9%
Supporting data
Prime contractor
#2 · 9.0% share
Newly active in this market; no actions were reported in the preceding 12 months
Related:Largest newly observed contractor
PIID 75A50126C00004
Modification

This action

+$145.1M

ADVANCED TECHNOLOGY INTERNATIONAL

BARDA - ASPR / DAAPPO / BARDA DCMA

OT TASK ORDER 8-RAPID PANDEMIC INFLUENZA AND EMERGING INFECTIOUS DISEASE VACCINE DEVELOPMENT AND RESPONSE CAPABILITY

Why it stands out

The award grew alongside stronger contractor activity.

The modification added $145.1M while contractor obligations rose $345.7M overall.

Award net obligations
$563.7M
Share of 12-month positive obligations
8.4%
Supporting data
Prime contractor
#3 · 8.4% share
+8.4 percentage points · $345.7M net increase; action accounted for 42.0%
PIID 75A50124F61008 · Mod P00004
Base award

This action

+$96.1M

KALEO, INC.

BARDA - ASPR / DAAPPO / BARDA DCMA

THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOINJECTORS (AS A DRUG/DEVICE COMBINATION PRODUCT) TO TREAT ORGANOPHOSPHATE (OP) POISONING, INCLUDING NERVE AGENT

Why it stands out

The contractor climbed 8 positions in this market.

It now ranks #5 by positive obligations over the latest 12 months.

Award net obligations
$96.1M
Share of 12-month positive obligations
5.5%
Supporting data
Prime contractor
#5 · 5.8% share
up 8 ranks · +3.7 percentage points · $73.8M net increase; action exceeded it by $22.2M
PIID 75A50126C00010
Modification

This action

+$66.0M

AMGEN USA INC

BARDA - ASPR / DAAPPO / BARDA DCMA

EO14398 FOR FAR 52.222-90, UPDATED HHSAR AND EXERCISE OPTION PERIOD 4A FOR $65,698,998.00

Why it stands out

The award grew alongside stronger contractor activity.

The modification added $66.0M while contractor obligations rose $36.1M overall.

Award net obligations
$839.9M
Share of 12-month positive obligations
3.8%
Supporting data
Prime contractor
#4 · 7.3% share
down 2 ranks · +0.1 percentage points · $36.1M net increase; action exceeded it by $29.9M
PIID 75A50122C00065 · Mod P00008
Modification

This action

+$25.2M

PPD DEVELOPMENT LP

NATIONAL INSTITUTES OF HEALTH NIAID

NIAID CLINICAL SITE MONITORING (NCSM)

Why it stands out

The contractor climbed 107 positions in this market.

It now ranks #10 by positive obligations over the latest 12 months.

Award net obligations
$73.2M
Share of 12-month positive obligations
1.4%
Supporting data
Prime contractor
#10 · 2.3% share
up 107 ranks · +2.3 percentage points · $39.4M net increase; action accounted for 63.8%
Funding office
#2 · 9.9% attributed share
−0.8 percentage points · $40.9M net increase; action accounted for 61.5%
Related:Largest rank gain
PIID 75N93024F00001 · Mod P00004
View recent award activity by date (10)
  1. EYDIS BIO, INC.Modification · PIID 75N93025C00040
    Action+$2.0M
    Award net obligations$2.5M
  2. VECTOR BIOSYSTEMS, INC.Deobligation · PIID 75N98C21K00033
    Action−$15
    Award net obligations$11K
  3. RESEARCH TRIANGLE INSTITUTEDeobligation · PIID 75D30122F00001
    Action−$3K
    Award net obligations$494K
  4. BRIGHAM & WOMENS HOSPITAL INCBase award · PIID 75F40126C00096
    Action+$1.5M
    Award net obligations$1.5M
  5. THE JOHNS HOPKINS UNIVERSITYDeobligation · PIID 75N95019C00058
    Action−$511K
    Award net obligations$765K
  6. ORGANOTHERAPEUTICS GMBHBase award · PIID 75F40126P00334
    Action+$254K
    Award net obligations$254K
  7. ADVANCED TECHNOLOGY INTERNATIONALModification · PIID 75A50124F61008
    Action+$145.1M
    Award net obligations$563.7M
  8. TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLCBase award · PIID 75F40126F19001
    Action+$1.2M
    Award net obligations$1.2M
  9. UNIVERSITY OF LIVERPOOLDeobligation · PIID 75F40120C00085
    Action−$611K
    Award net obligations$8.8M
  10. UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONDeobligation · PIID 75N95019C00047
    Action−$231K
    Award net obligations$14.0M

HHS research and development in biotechnology (except nanobiotechnology) market FAQs

Answers based on reported federal contract data.

Who are the top HHS research and development in biotechnology (except nanobiotechnology) contractors?

In the 12 months through October 23, 2026, ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE), SHIONOGI INC, and ADVANCED TECHNOLOGY INTERNATIONAL were the leading HHS research and development in biotechnology (except nanobiotechnology) prime contractors by positive obligations.

  1. #1

    ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

    $266,201,801 in positive obligations

  2. #2

    SHIONOGI INC

    $156,103,541 in positive obligations

  3. #3

    ADVANCED TECHNOLOGY INTERNATIONAL

    $145,075,949 in positive obligations

Rankings use reported USAspending award data.

Did HHS contract obligations increase under NAICS 541714?

Yes. Measured by net prime contract obligations, reported HHS activity in the research and development in biotechnology (except nanobiotechnology) market increased 71.1% from $986,397,417 in the preceding 12 months to $1,688,148,653 in the 12 months through October 23, 2026.

Latest 12 months
$1,688,148,653
Net prime contract obligations
Preceding 12 months
$986,397,417
Net prime contract obligations
Change
+71.1%
Between matched 12-month periods

Reported contract actions, not outlays or a forecast.

What recent HHS contract award activity was reported under NAICS 541714?

Recent HHS contract award activity reported in the research and development in biotechnology (except nanobiotechnology) market included actions for ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE), SHIONOGI INC, and ADVANCED TECHNOLOGY INTERNATIONAL during the 12 months through October 23, 2026.

Action obligations are transaction-level amounts, not current award-level obligations.

Which procurement methods were reported for HHS contracts under NAICS 541714?

From October 24, 2025 through October 23, 2026, HHS reported 325 positive-obligation awards for research and development in biotechnology (except nanobiotechnology) under NAICS 541714. The leading award type was definitive contract. The leading reported procedure was np.

Positive-obligation awards
325
Leading reported procedure
Np
69.4% of positive obligations
Leading award type
Definitive Contract
79.7% of positive obligations
Full and open
25%
of positive obligations
Reported parent IDV
19.9%
of positive obligations
Observed vehicles
CARRRP and BARDA Nonclinical Development Biological
Exact matches from reported parent PIIDs

Percentages use positive obligations as the denominator.

Which HHS research and development in biotechnology (except nanobiotechnology) awards may warrant recompete research?

6 HHS research and development in biotechnology (except nanobiotechnology) awards may warrant recompete research based on reported potential-end dates, including awards held by RHO FEDERAL SYSTEMS DIVISION INC, DELOITTE CONSULTING LLP, and CRESTONE, INC.

Research leads, not confirmed recompetes. Dates may change through later modifications.

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Leading-prime vehicle memberships:

Company memberships do not establish award-channel use.

Reported obligations include contract actions from October 1, 2021 through October 23, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology